Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 13/20 | 0.49 |
| ▸ | LGMN | Q99538 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19030064 | 0.94 | IRAK4 (0.47) | IRAK4LGMNKDM4EALDH1A1LMNA | |
| SCHEMBL19029997 | 0.91 | IRAK4 (0.47) | IRAK4LGMNKDM4EGAAMAPT | |
| SCHEMBL19030334 | 0.85 | IRAK4 (0.45) | IRAK4LGMNKDM4EGAAMAPT | |
| SCHEMBL19046250 | 0.83 | IRAK4 (0.58) | IRAK4 | |
| SCHEMBL19046031 | 0.82 | IRAK4 (0.50) | IRAK4LGMNKDM4EALDH1A1LMNA | |
| SCHEMBL19030539 | 0.81 | IRAK4 (0.48) | IRAK4KDM4EGAAMAPTMAPK1 | |
| SCHEMBL28670293 | 0.81 | IRAK4 (0.48) | IRAK4LGMNKDM4EGAAMAPT | |
| SCHEMBL19029917 | 0.81 | IRAK4 (0.52) | IRAK4LGMNKDM4EALDH1A1 | |
| SCHEMBL19030684 | 0.80 | LGMN (0.45) | IRAK4LGMN | |
| SCHEMBL19029902 | 0.79 | IRAK4 (0.42) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332718-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | GENENTECH, INC. (US) | 2022-10-20 | — | — | US | disclosed |
| US-10988478-B1 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | GENENTECH, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-10988478-B1 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | GENENTECH, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| EP-3394066-A2 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | H. Hoffnabb-La Roche Ag (CH) | 2018-10-31 | — | — | EP | disclosed |
| US-20180298015-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | GENENTECH, INC. (US) | 2018-10-18 | — | — | US | disclosed |
| WO-2017108723-A2 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-29 | — | — | WO | disclosed |
| WO-2017108723-A2 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180298015-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK1, IRAK4, IRAK2 | IRAK4 2/4885LGMN 4819/4885KDM4E 463/4885 |
| US-20220332718-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK1, IRAK4, IRAK2 | IRAK4 2/4885LGMN 4832/4885KDM4E 662/4885 |
| US-10988478-B1 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | IRAK1, IRAK4, IRAK2 | IRAK4 2/4885LGMN 4819/4885KDM4E 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.